8-KAnnualMeetingMay2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________
FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 6, 2013
    
ALEXION PHARMACEUTICALS, INC.
-----------------------------------------------------------
(Exact name of registrant as specified in its charter)

Delaware
000-27756
13-3648318
------------------
------------------
---------------
(State or other jurisdiction of
of incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification No.)


352 Knotter Drive, Cheshire, Connecticut 06410
---------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code:    (203) 272-2596
   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨
Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))






Item 5.07    Submission of Matters to a Vote of Security Holders.
Alexion Pharmaceuticals, Inc. held its Annual Meeting of Stockholders on May 6, 2013 in New Haven, Connecticut. The results of the matters voted on by the stockholders are set forth below.

1.    The election of directors:
 

Votes For
 
Votes Against or Withheld
 
Broker
Non-Votes
 
 
 
 
 
 
Max Link
164,511,744
 
6,560,957
 
6,179,834
Leonard Bell
165,446,286
 
5,626,415
 
6,179,834
William R. Keller
165,790,924
 
5,281,777
 
6,179,834
Joseph A. Madri
164,192,413
 
6,880,288
 
6,179,834
Larry L. Mathis
166,331,290
 
4,741,411
 
6,179,834
R. Douglas Norby
164,312,167
 
6,760,534
 
6,179,834
Alvin S. Parven
164,157,547
 
6,915,154
 
6,179,834
Andreas Rummelt
166,528,043
 
4,544,658
 
6,179,834
Ann M. Veneman
165,840,413
 
5,232,288
 
6,179,834

2.
The non-binding advisory vote to approve the compensation paid to Alexion’s named executive officers as described in Alexion’s 2013 proxy statement:

Votes For
 

Votes Against
 

Abstentions
 
 
 
 
 
150,650,744
 
20,215,326
 
206,631

3.
Approval of the Amended and Restated 2004 Incentive Plan, including an amendment to increase the number of shares of common stock available for issuance by 12 million shares:

Votes For
 

Votes Against
 

Abstentions
 
 
 
 
 
152,111,375
 
18,753,145
 
208,181

4.
Ratification of the appointment of PricewaterhouseCoopers LLP as Alexion's independent registered public accounting firm:

Votes For
 

Votes Against
 

Abstentions
 
 
 
 
 
174,112,707
 
3,021,572
 
118,256





Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 10, 2013
 
ALEXION PHARMACEUTICALS, INC.
 
 
By:    /s/ Michael V. Greco
Name: Michael V. Greco
Title: Associate General Counsel and Corporate Secretary